Compare Stocks: TLSA, EPRX, PBYI, and KMDA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EPRX Eupraxia Pharmaceuticals	$8.40 +12.0%	$6.68	$5.15 ▼ $9.32	$487.64M	1.07	357,777 shs	3.52 million shs
KMDA Kamada	$8.54 +3.3%	$7.51	$6.50 ▼ $9.35	$475.57M	0.88	181,532 shs	160,683 shs
PBYI Puma Biotechnology	$9.55 +1.5%	$8.53	$4.30 ▼ $9.73	$485.74M	1.24	323,338 shs	185,909 shs
TLSA Tiziana Life Sciences	$1.02 +4.7%	$1.08	$0.87 ▼ $2.35	$124.01M	0.52	966,844 shs	573,921 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EPRX Eupraxia Pharmaceuticals	+12.00%	+25.75%	+29.63%	+41.18%	+55.56%
KMDA Kamada	+3.26%	+3.02%	+18.94%	+19.11%	+22.53%
PBYI Puma Biotechnology	+1.49%	+5.41%	+19.52%	+35.85%	+86.16%
TLSA Tiziana Life Sciences	+4.67%	+0.99%	+3.03%	-17.74%	-41.71%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EPRX Eupraxia Pharmaceuticals	$8.40 +12.0%	$6.68	$5.15 ▼ $9.32	$487.64M	1.07	357,777 shs	3.52 million shs
KMDA Kamada	$8.54 +3.3%	$7.51	$6.50 ▼ $9.35	$475.57M	0.88	181,532 shs	160,683 shs
PBYI Puma Biotechnology	$9.55 +1.5%	$8.53	$4.30 ▼ $9.73	$485.74M	1.24	323,338 shs	185,909 shs
TLSA Tiziana Life Sciences	$1.02 +4.7%	$1.08	$0.87 ▼ $2.35	$124.01M	0.52	966,844 shs	573,921 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EPRX Eupraxia Pharmaceuticals	+12.00%	+25.75%	+29.63%	+41.18%	+55.56%
KMDA Kamada	+3.26%	+3.02%	+18.94%	+19.11%	+22.53%
PBYI Puma Biotechnology	+1.49%	+5.41%	+19.52%	+35.85%	+86.16%
TLSA Tiziana Life Sciences	+4.67%	+0.99%	+3.03%	-17.74%	-41.71%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EPRX Eupraxia Pharmaceuticals	2.89	Moderate Buy	$18.00	114.29% Upside
KMDA Kamada	3.00	Buy	$13.00	52.22% Upside
PBYI Puma Biotechnology	2.00	Hold	$6.00	-37.17% Downside
TLSA Tiziana Life Sciences	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest TLSA, EPRX, PBYI, and KMDA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/3/2026	TLSA Tiziana Life Sciences	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
8/26/2026	TLSA Tiziana Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/21/2026	PBYI Puma Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
8/7/2026	PBYI Puma Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
8/7/2026	PBYI Puma Biotechnology	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$5.00 ➝ $6.00
7/21/2026	KMDA Kamada	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/21/2026	KMDA Kamada	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$15.00
7/17/2026	EPRX Eupraxia Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/15/2026	EPRX Eupraxia Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
7/14/2026	TLSA Tiziana Life Sciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
6/25/2026	EPRX Eupraxia Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$17.00

(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	$1.54 per share	N/A
KMDA Kamada	$180.46M	2.72	$0.63 per share	13.54	$4.69 per share	1.82
PBYI Puma Biotechnology	$228.40M	2.16	$0.85 per share	11.28	$2.68 per share	3.56
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EPRX Eupraxia Pharmaceuticals	-$38.58M	-$1.02	N/A	N/A	N/A	N/A	-63.97%	-43.32%	11/3/2026 (Estimated)
KMDA Kamada	$20.20M	$0.38	22.47	14.23	0.68	11.60%	8.37%	5.85%	11/9/2026 (Estimated)
PBYI Puma Biotechnology	$31.11M	$0.52	18.37	68.21	N/A	11.50%	20.76%	13.22%	11/5/2026 (Estimated)
TLSA Tiziana Life Sciences	-$18.43M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	9/18/2026 (Estimated)

Latest TLSA, EPRX, PBYI, and KMDA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/18/2026	N/A	TLSA Tiziana Life Sciences	-$0.0783	N/A	N/A	N/A	N/A	N/A
8/12/2026	Q2 2026	KMDA Kamada	$0.1125	$0.16	+$0.0475	$0.16	$50.84 million	$54.92 million
8/11/2026	Q2 2026	EPRX Eupraxia Pharmaceuticals	-$0.25	-$0.23	+$0.02	-$0.23	N/A	N/A
8/6/2026	Q2 2026	PBYI Puma Biotechnology	$0.04	$0.19	+$0.15	$0.16	$53.00 million	$56.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KMDA Kamada	$0.13	1.52%	N/A	34.21%	N/A
PBYI Puma Biotechnology	N/A	N/A	N/A	N/A	N/A
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	N/A

Latest TLSA, EPRX, PBYI, and KMDA Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/17/2026	KMDA Kamada	annual	$0.17	2.06%	8/27/2026	8/27/2026	9/17/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EPRX Eupraxia Pharmaceuticals	0.02	16.00	16.00
KMDA Kamada	N/A	4.06	2.29
PBYI Puma Biotechnology	N/A	2.91	2.64
TLSA Tiziana Life Sciences	N/A	0.76	0.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EPRX Eupraxia Pharmaceuticals	N/A
KMDA Kamada	20.38%
PBYI Puma Biotechnology	61.29%
TLSA Tiziana Life Sciences	N/A

Insider Ownership

Company	Insider Ownership
EPRX Eupraxia Pharmaceuticals	N/A
KMDA Kamada	36.10%
PBYI Puma Biotechnology	22.20%
TLSA Tiziana Life Sciences	39.82%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EPRX Eupraxia Pharmaceuticals	29	65.02 million	N/A	N/A
KMDA Kamada	360	57.51 million	36.75 million	Optionable
PBYI Puma Biotechnology	200	51.62 million	40.16 million	Optionable
TLSA Tiziana Life Sciences	8	127.26 million	76.58 million	Optionable

TLSA, EPRX, PBYI, and KMDA Headlines

Recent News About These Companies

BTIG initiates coverage of Tiziana Life Sciences (TLSA) with buy rating

September 3 at 11:56 PM | msn.com

Tiziana Life Sciences gets Buy rating from BTIG on Treg-based approach to neurodegeneration

September 3 at 3:27 PM | proactiveinvestors.com

Tiziana Life Sciences (NASDAQ:TLSA) Stock Price Down 0.9% - Should You Sell?

August 28, 2026 | marketbeat.com

Tiziana Life Sciences to present Phase 2a BANYAN trial data at ALS Nexus 2026

August 24, 2026 | proactiveinvestors.com

Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026

August 24, 2026 | globenewswire.com

Insider Buying: Tiziana Life Sciences (NASDAQ:TLSA) CEO Acquires $81,292.79 in Stock

August 7, 2026 | insidertrades.com

Insider Buying: Tiziana Life Sciences (NASDAQ:TLSA) CEO Purchases 83,807 Shares of Stock

August 6, 2026 | marketbeat.com

Ivor Elrifi Acquires 237,616 Shares of Tiziana Life Sciences (NASDAQ:TLSA) Stock

August 6, 2026 | marketbeat.com

Tiziana Life Sciences (NASDAQ:TLSA) CEO Purchases $667,000.00 in Stock

August 6, 2026 | insidertrades.com

Tiziana Life Sciences Ltd.: Tiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab

August 2, 2026 | finanznachrichten.de

Tiziana Life Sciences Says Imaging Results Show Neuroinflammation Reduction in Rare Neurodegenerative Condition

July 31, 2026 | benzinga.com

Tiziana Life Sciences reports reductions in brain inflammation in third MSA patient

July 31, 2026 | proactiveinvestors.com

Tiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab

July 31, 2026 | finance.yahoo.com

Tiziana Life Sciences (NASDAQ:TLSA) Stock, Short Interest Report

July 13, 2026 | benzinga.com

Tiziana Life Sciences doses last patient in Phase 2a multiple sclerosis trial

June 25, 2026 | proactiveinvestors.com

Tiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS Trial

June 25, 2026 | globenewswire.com

Why Tiziana Life Sciences Is Back on the Small-Cap Radar?

June 19, 2026 | kalkinemedia.comK

Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman

June 15, 2026 | globenewswire.com

Tiziana Life Sciences Ltd.: Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York

May 29, 2026 | finanznachrichten.de

Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York

May 28, 2026 | globenewswire.com

Tiziana Life Sciences advances foralumab program with full Phase 2 enrollment and encouraging expanded access data â€“ ICYMI

May 22, 2026 | proactiveinvestors.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLSA, EPRX, PBYI, and KMDA Company Descriptions

Eupraxia Pharmaceuticals NASDAQ:EPRX

$8.40 +0.90 (+12.00%)

As of 09/4/2026 04:00 PM Eastern

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

Kamada NASDAQ:KMDA

$8.54 +0.27 (+3.26%)

As of 09/4/2026 04:00 PM Eastern

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Puma Biotechnology NASDAQ:PBYI

$9.55 +0.14 (+1.49%)

As of 09/4/2026 04:00 PM Eastern

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Tiziana Life Sciences NASDAQ:TLSA

$1.02 +0.05 (+4.67%)

As of 09/4/2026 04:00 PM Eastern

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TLSA, EPRX, PBYI, and KMDA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TLSA, EPRX, PBYI, and KMDA Earnings

Compare Dividends

Latest TLSA, EPRX, PBYI, and KMDA Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TLSA, EPRX, PBYI, and KMDA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLSA, EPRX, PBYI, and KMDA Company Descriptions

Eupraxia Pharmaceuticals NASDAQ:EPRX

Kamada NASDAQ:KMDA

Puma Biotechnology NASDAQ:PBYI

Tiziana Life Sciences NASDAQ:TLSA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TLSA, EPRX, PBYI, and KMDA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TLSA, EPRX, PBYI, and KMDA Earnings

Compare Dividends

Latest TLSA, EPRX, PBYI, and KMDA Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TLSA, EPRX, PBYI, and KMDA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLSA, EPRX, PBYI, and KMDA Company Descriptions

Eupraxia Pharmaceuticals NASDAQ:EPRX

Kamada NASDAQ:KMDA

Puma Biotechnology NASDAQ:PBYI

Tiziana Life Sciences NASDAQ:TLSA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools